Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models. These models often fail to accurately represent the intricate biology of human patients. 

This webinar explores how patient-derived organoids (HUB Organoids) are revolutionising drug discovery by overcoming these challenges.

HUB Organoids faithfully recapitulate patient-specific pathobiology. They remain genetically stable over passages and readily incorporate genetic modifications. This unique combination bridges the gap between the lab and the clinic, enabling the development of more effective therapies.

An audience Q&A session with the presenter follows the webinar presentations.

Watch the webinar on-demand now!